Herold Duroseau
Pediatric Hematology-Oncology · Brooklyn, NYNPI 1811998883
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 10.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $737, 3.9 times the $190 reported in 2019.
Across 107 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$264
- Supernus Pharmaceuticals, Inc.$236
- Corium, LLC$169
- Pfizer$139
- Luye Pharma (USA) Ltd.$130
- Biomarin Pharmaceutical Inc.$127
- plus $1K from 28 others
What the payments were for
- Food & beverage$2,423100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 11 | $264 |
| Supernus Pharmaceuticals, Inc. | 13 | $236 |
| Corium, LLC | 13 | $169 |
| Pfizer | 6 | $139 |
| Luye Pharma (USA) Ltd. | 1 | $130 |
| Biomarin Pharmaceutical Inc. | 5 | $127 |
| Alkermes, Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| UCB, Inc. | 6 | $89 |
| Baxter Healthcare | 5 | $87 |
| Amphastar Pharmaceuticals, Inc. | 4 | $80 |
| AstraZeneca | 4 | $78 |
| Sanofi | 4 | $72 |
| Ironshore Pharmaceuticals Inc. | 4 | $62 |
| Medtronic | 1 | $59 |
| GSK | 3 | $50 |
| Novartis | 2 | $48 |
| Philips North America LLC | 2 | $47 |
| Endo USA, Inc. | 2 | $44 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Mirum Pharmaceuticals, Inc. | 2 | $41 |
| Novo Nordisk | 2 | $39 |
| Tandem Diabetes Care, Inc. | 2 | $37 |
| Zealand Pharma US, Inc. | 1 | $29 |
| Celltrion USA Inc. | 1 | $28 |
| Tolmar, Inc. | 1 | $22 |
| Catalyst Pharmaceuticals, Inc. | 1 | $22 |
| Zogenix Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Greenwich Biosciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$500
- ERZOFRI EXTENDED-RELEASE$130
- ARISTADA INITIO$125
- VOQUEZNA$125
- OXBRYTA$122
How this compares
$2,423 in reported general payments places this provider in the 65th percentile of 196 pediatric hematology-oncology providers in New York.
See all pediatric hematology-oncology providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $6,317 |
Paid to pharmacies, not to this prescriber.
Other pediatric hematology-oncology in Brooklyn
- Kusum ViswanathanBrooklyn$43K
- Shipra KaickerBrooklyn$14K
- Arpan SinhaBrooklyn$3K
- Mitchell CairoHawthorne$1.1M
- Sujit ShethNew York$359K
- Jaap Jan BoelensNew York$303K
- Mary SugrueGarden City$253K
- James BusselNew York$204K
- Saara KavianyNew York$144K
- Gary BrittenhamNew York$137K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.